(NP (NP (ADJP (NN Sterol) (JJ dependent)) (NN LDL-receptor) (NN gene) (NN transcription)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (UCP-COOD (ADJP (JJ normal)) (CC and) (NP (NN CML))) (NNS patients))))) (. .))
(S (NP-SBJ-61 (NP (NN Sterol) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN SRE)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN recognized) (S (NP-SBJ (-NONE- *-61)) (VP (TO to) (VP (VB regulate) (NP (NP (JJ various) (JJ key) (NNS genes)) (VP (VBG coding) (PP (IN for) (NP (NP-COOD (NP (ADJP (RB especially) (JJ low)) (NN density) (NN lipoprotein) (-LRB- -LRB-) (NN LDL) (-RRB- -RRB-) (NN -receptor)) (, ,) (NP (NP (NN 3-hydroxy-3-methylglutaryl) (NN coenzyme) (NN A)) (PRN (-LRB- -LRB-) (NP (NN HMG-CoA)) (-RRB- -RRB-)) (NN reductase)) (CC and) (NP (NN HMG-CoA) (NN synthase))) (VP (VBN known) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB play) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (DT the) (NN cholesterol) (NN feedback) (NN mechanism))))))))))))))))) (. .))
(S (NP-SBJ-62 (DT The) (JJ deranged) (NN cholesterol) (NN feedback) (NN mechanism)) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB widely)) (VBN recognised) (NP (-NONE- *-62)) (PP (IN in) (NP (NP-COOD (NP (NN initiation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN progression))) (PP (IN of) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NNS cancers))) (PP (VBG including) (NP (NP (JJ chronic) (JJ myeloid) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN CML)) (-RRB- -RRB-))))))))))) (. .))
(S (ADVP (RB Consequently)) (, ,) (NP-SBJ-110 (DT the) (JJ present) (NN study)) (VP-COOD (VP (VBD was) (VP (VBN addressed) (NP (-NONE- *-110)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB understand) (NP (DT this) (NN phenomenon))))))) (CC and) (VP (VBD revealed) (NP-COOD (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT this) (NN SRE) (NN sequence))))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ normal) (NNS subjects)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (PRP$ its) (NN absence)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ untreated) (NN CML) (NNS patients))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ (DT this) (NN factor)) (VP (VBD appeared) (SBAR-TMP (WHADVP-63 (WRB when)) (S (NP-SBJ (DT the) (NN CML) (NNS patients)) (VP (VBD achieved) (NP (NP (JJ complete) (JJ haematological) (NN remission)) (PRN (-LRB- -LRB-) (NP (NN CHR)) (-RRB- -RRB-))) (PP (IN through) (NP (NN alpha-interferon) (NN therapy))) (ADVP (-NONE- *T*-63)))))) (. .))
(S (ADVP (RB Further)) (, ,) (NP-SBJ-64 (DT an) (NN inverse) (NN relationship)) (VP (VBD was) (VP (ADVP (RB also)) (VBN observed) (NP (-NONE- *-64)) (PP (IN between) (NP-COOD (NP (ADJP (NN sterol) (JJ modulated)) (NN LDL-receptor) (NN gene) (NN transcription)) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (DT this) (ADJP (CD 47) (NN kDa)) (NN factor))) (PP (TO to) (NP (DT the) (NN SRE) (NN sequence)))))))) (. .))
(S (PP (VBN Based) (PP (IN upon) (NP (DT these) (NNS results)))) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (NN alpha-interferon)) (PP (IN through) (NP (PRP$ its) (NN receptor))) (VP (VBZ initiates) (NP (NP (ADJP (NP (JJ phosphatidic) (NN acid)) (JJ dependent)) (NN signalling)) (SBAR (WHNP-66 (WDT which)) (S (PP (IN in) (NP (NN turn))) (NP-SBJ (-NONE- *T*-66)) (VP (VBZ regulates) (NP-COOD (NP (NP (DT the) (NN affinity)) (PP (IN of) (NP (ADJP (CD 47) (NN kDa)) (NN sterol) (JJ regulatory) (NN element) (NN binding) (NN factor)))) (CONJP (RB as) (RB well) (IN as)) (NP (NN LDL-receptor) (NN gene) (NN transcription)))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (NN CML) (NNS patients)))))))))) (. .))
